UBRELVY 50 mg/1

UBRELVY 50 mg is a medication containing ubrogepant, used for the acute treatment of migraines. This oral tablet is designed to provide relief from migraine symptoms. Ubrogepant is a selective calcitonin gene-related peptide (CGRP) receptor antagonist.

UBRELVY 50 mg is primarily used for the acute treatment of migraines in adults. It is designed to alleviate the pain and other symptoms associated with migraines. Ubrogepant works by blocking the activity of CGRP, a molecule involved in migraine attacks. This medication is not intended for preventive use but rather for the treatment of migraine episodes as they occur.

Common effects of Ubrevly 50 mg may include nausea, somnolence, and dry mouth. Some users may experience fatigue or dizziness. These effects are generally mild to moderate and may vary from person to person. It is important to consult with a healthcare provider if any effects are severe or persistent.

UBRELVY 50 mg should be used with caution in individuals with liver impairment. It is important to inform your healthcare provider about any other medications you are taking, including over-the-counter drugs and supplements. This medication should not be used for the prevention of migraines but rather for the treatment of acute migraine episodes.

UBRELVY 50 mg may interact with other medications, including those metabolized by the liver enzyme CYP3A. It is important to avoid grapefruit and grapefruit juice, as they can affect the metabolism of ubrogepant. Always consult with a healthcare provider before starting any new medication, especially if you are taking other prescription drugs.